$JANX
Janux Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022008984 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $2.365M $1.589M $1.616M
YoY Change 390.66% 318.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.540M $4.947M $3.937M
YoY Change 177.42% 569.42% 487.61%
% of Gross Profit
Research & Development $14.09M $10.18M $11.17M
YoY Change 197.36% 429.04% 1028.18%
% of Gross Profit
Depreciation & Amortization $108.0K $81.00K $64.00K
YoY Change 730.77% 800.0% 611.11%
% of Gross Profit
Operating Expenses $19.63M $10.18M $15.11M
YoY Change 314.31% 429.04% 812.75%
Operating Profit -$17.26M -$13.54M
YoY Change 176.09% 492.91%
Interest Expense $373.0K $132.0K $74.00K
YoY Change 710.87%
% of Operating Profit
Other Income/Expense, Net $373.0K $132.0K
YoY Change 710.87%
Pretax Income -$16.89M -$13.41M -$13.42M
YoY Change 172.12% 487.13% 710.63%
Income Tax
% Of Pretax Income
Net Earnings -$16.89M -$13.41M -$13.42M
YoY Change 172.12% 487.13% 710.63%
Net Earnings / Revenue -714.08% -843.93% -830.2%
Basic Earnings Per Share -$0.41 -$0.32
Diluted Earnings Per Share -$407.4K -$324.6K -$324.0K
COMMON SHARES
Basic Shares Outstanding 41.63M 307.8K 41.61M
Diluted Shares Outstanding 41.45M 41.32M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $354.3M $361.2M $375.0M
YoY Change -10.12% 410.39%
Cash & Equivalents $58.40M $55.13M $35.58M
Short-Term Investments $295.9M $306.1M $339.4M
Other Short-Term Assets $3.769M $3.454M $2.054M
YoY Change 84.94% 1218.32%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00
Total Short-Term Assets $358.1M $364.7M $377.0M
YoY Change -9.72% 410.68% 2247.27%
LONG-TERM ASSETS
Property, Plant & Equipment $26.28M $2.660M $1.412M
YoY Change 12121.86% 1605.13% 810.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.023M $337.0K $392.0K
YoY Change 31.13%
Total Long-Term Assets $27.30M $3.943M $2.805M
YoY Change 12597.67% 854.72% 1709.68%
TOTAL ASSETS
Total Short-Term Assets $358.1M $364.7M $377.0M
Total Long-Term Assets $27.30M $3.943M $2.805M
Total Assets $385.4M $368.6M $379.8M
YoY Change -2.89% 413.23% 2242.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $1.939M $2.458M
YoY Change 747.46% 126.25% 474.3%
Accrued Expenses $4.131M $5.074M $3.779M
YoY Change 80.71% 603.74% 403.2%
Deferred Revenue $4.649M $5.163M
YoY Change 164.77%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.99M $12.52M $12.80M
YoY Change 41.16% 81.53% 302.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $28.56M $0.00 $700.0K
YoY Change 911.58% -100.0%
Total Long-Term Liabilities $28.56M $0.00 $700.0K
YoY Change 911.58% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.99M $12.52M $12.80M
Total Long-Term Liabilities $28.56M $0.00 $700.0K
Total Liabilities $41.55M $12.52M $13.50M
YoY Change 245.45% 11.3% 46.21%
SHAREHOLDERS EQUITY
Retained Earnings -$60.80M -$47.41M
YoY Change 221.67%
Common Stock $418.5M $414.0M
YoY Change 409808.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $343.8M $356.1M $366.3M
YoY Change
Total Liabilities & Shareholders Equity $385.4M $368.6M $379.8M
YoY Change -2.89% 413.23% 2242.13%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$16.89M -$13.41M -$13.42M
YoY Change 172.12% 487.13% 710.63%
Depreciation, Depletion And Amortization $108.0K $81.00K $64.00K
YoY Change 730.77% 800.0% 611.11%
Cash From Operating Activities -$6.073M -$11.52M -$10.48M
YoY Change -2.11% -307.12% 543.4%
INVESTING ACTIVITIES
Capital Expenditures -$898.0K $971.0K -$1.173M
YoY Change 1036.71% 534.64%
Acquisitions
YoY Change
Other Investing Activities $9.937M $32.04M $8.499M
YoY Change -106.97%
Cash From Investing Activities $9.039M $31.07M $7.326M
YoY Change -106.34% -20405.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 308.0K 1.000K 164.0K
YoY Change -99.91% -100.0% -96.4%
NET CHANGE
Cash From Operating Activities -6.073M -11.52M -10.48M
Cash From Investing Activities 9.039M 31.07M 7.326M
Cash From Financing Activities 308.0K 1.000K 164.0K
Net Change In Cash 3.274M 19.55M -2.991M
YoY Change -98.19% -68.95% -202.29%
FREE CASH FLOW
Cash From Operating Activities -$6.073M -$11.52M -$10.48M
Capital Expenditures -$898.0K $971.0K -$1.173M
Free Cash Flow -$5.175M -$12.49M -$9.308M
YoY Change -15.51% -330.92% 471.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001817713
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-40475
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Janux Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2289112
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11099 N. Torrey Pines Road, Suite 290
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
750-4700
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55129000
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
JANX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41629367
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
306071000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
339383000
CY2022Q1 janx Prepaid Expenses And Other Current Assets Related Parties Current
PrepaidExpensesAndOtherCurrentAssetsRelatedPartiesCurrent
23000
CY2021Q4 janx Prepaid Expenses And Other Current Assets Related Parties Current
PrepaidExpensesAndOtherCurrentAssetsRelatedPartiesCurrent
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3454000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2054000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
364654000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
377019000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
816000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
816000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2660000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
130000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
185000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
337000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000
CY2022Q1 us-gaap Assets
Assets
368597000
CY2021Q4 us-gaap Assets
Assets
379824000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1939000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000
CY2022Q1 janx Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
0
CY2021Q4 janx Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
32000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5074000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4649000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5163000
CY2022Q1 janx Unvested Stock Liabilities
UnvestedStockLiabilities
700000
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
194000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12515000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12797000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
700000
CY2022Q1 us-gaap Liabilities
Liabilities
12515000
CY2021Q4 us-gaap Liabilities
Liabilities
13497000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41629367
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41622962
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41393660
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41243137
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
418429000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413967000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1567000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-270000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60821000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47411000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
356082000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368597000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379824000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1589000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
380000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10184000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1925000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4947000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
739000
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15131000
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2664000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13542000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2284000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
132000
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
0
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
132000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-13410000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-14977000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2284000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2284000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1567000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41315482
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1111178
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
366327000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
503000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3958000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1297000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13410000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
356082000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-14638000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
8000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2284000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-16771000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-13410000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2284000
CY2022Q1 us-gaap Depreciation
Depreciation
81000
CY2021Q1 us-gaap Depreciation
Depreciation
9000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3958000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
123000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
24000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7625000
CY2022Q1 janx Prepaid Expenses And Other Current Assets Includes Related Party Amounts
PrepaidExpensesAndOtherCurrentAssetsIncludesRelatedPartyAmounts
23000
CY2021Q1 janx Prepaid Expenses And Other Current Assets Includes Related Party Amounts
PrepaidExpensesAndOtherCurrentAssetsIncludesRelatedPartyAmounts
-50000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1400000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-55000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-740000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
347000
CY2022Q1 janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
-32000
CY2021Q1 janx Accrued Expenses Includes Related Party Amounts
AccruedExpensesIncludesRelatedPartyAmounts
-544000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1158000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-240000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1214000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4000
CY2022Q1 janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-14000
CY2021Q1 janx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
0
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11522000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5563000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
971000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
45061000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
77100000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31068000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-153000
CY2022Q1 janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
1000
CY2021Q1 janx Proceeds From Exercise Of Vested And Unvested Common Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfVestedAndUnvestedCommonStockOptionsAndEmployeeStockPurchasePlan
1646000
CY2022Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0
CY2021Q1 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
100000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57546000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
19547000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
62956000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7813000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55945000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70769000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
396000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
CY2022Q1 janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
503000
CY2021Q1 janx Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
8000
CY2022Q1 us-gaap Stock Issued1
StockIssued1
0
CY2021Q1 us-gaap Stock Issued1
StockIssued1
278000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1297000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
Company’s certificate of incorporation to effect a forward split of shares of the Company’s common stock on a one-for-1.281 basis, which was effected on June 4, 2021 (the “Forward Stock Split”). The number of authorized shares and the par values of the common stock and convertible preferred stock were not adjusted as a result of the Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the Forward Stock Split for all periods presented
CY2022Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.281
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
365217000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60800000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">significant </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">estimates in the Company’s financial statements relate to estimates to complete the performance obligations and the estimated transaction price for collaboration revenue, accruals for research and development expenses, stock-based compensation and fair value measurements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Although the impact of the COVID-19 pandemic to the Company’s business and operating results presents additional uncertainty, the Company continues to use the best information available to update its accounting estimates. Actual results may differ materially and adversely from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35171000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306071000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
816000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
342058000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25018000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
267122000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55129000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35582000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
816000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
816000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55945000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36398000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
307638000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1567000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306071000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
339653000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
339383000
CY2022Q1 us-gaap Financing Receivable Accrued Interest Before Allowance For Credit Loss
FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss
100000
CY2021Q4 us-gaap Financing Receivable Accrued Interest Before Allowance For Credit Loss
FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss
200000
CY2022Q1 janx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
38949000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
291267000
CY2021Q4 janx Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
48116000
CY2022Q1 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2021Q4 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2021Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19109405
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has not experienced any losses in such account and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is also subject to credit risk from its accounts receivable. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. As of March 31, 2022, and December 31, 2021, all of the Company’s accounts receivable, if any, relate to a single customer. For the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, all of the Company’s revenue related to a single customer.</span>
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
307765
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
304303
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7381599
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2872000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1543000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
212000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
131000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2660000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1412000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
805000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1171000
CY2022Q1 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3937000
CY2021Q4 janx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2130000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
332000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
478000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5074000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3779000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
154000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
154000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
153000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedRemainderOfFiscalYear
0
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextTwelveMonths
3040000
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Two Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextTwoYears
3412000
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Three Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextThreeYears
3514000
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Next Four Years
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueNextFourYears
3620000
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsNotYetCommencedDueThereafter
24115000
CY2022Q1 janx Lessee Operating Lease Liability Payments Not Yet Commenced
LesseeOperatingLeaseLiabilityPaymentsNotYetCommenced
37701000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654663
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.65
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
62954000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1611590
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.54
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6405
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.11
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
137628
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.46
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7122220
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.82
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M28D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35024000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7122220
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.82
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M28D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
35024000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4982978
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.35
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y11M4D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
35024000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.02
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.12
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000.0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
52800000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 janx Percentage Of Number Of Common Stock Shares
PercentageOfNumberOfCommonStockShares
0.01
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3958000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
123000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
379825
CY2021Q4 janx Unvested Stock Liabilities
UnvestedStockLiabilities
1203000
CY2022Q1 janx Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
0
CY2022Q1 janx Unvested Stock Liabilities Early Exercised Shares
UnvestedStockLiabilitiesEarlyExercisedShares
0
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
144118
CY2022Q1 janx Unvested Stock Liabilities Vested Shares
UnvestedStockLiabilitiesVestedShares
503000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
235707
CY2022Q1 janx Unvested Stock Liabilities
UnvestedStockLiabilities
700000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y

Files In Submission

Name View Source Status
0000950170-22-008984-index-headers.html Edgar Link pending
0000950170-22-008984-index.html Edgar Link pending
0000950170-22-008984.txt Edgar Link pending
0000950170-22-008984-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
janx-20220331.htm Edgar Link pending
janx-20220331.xsd Edgar Link pending
janx-20220331_cal.xml Edgar Link unprocessable
janx-20220331_def.xml Edgar Link unprocessable
janx-20220331_htm.xml Edgar Link completed
janx-20220331_lab.xml Edgar Link unprocessable
janx-20220331_pre.xml Edgar Link unprocessable
janx-ex31_1.htm Edgar Link pending
janx-ex31_2.htm Edgar Link pending
janx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending